RBC Capital Raises Target Price for Abbott to $130

Author's Avatar
2 days ago
Article's Main Image

RBC Capital has recently adjusted its outlook on Abbott Laboratories (ABT, Financial), increasing its target price from $125 to $130. The firm continues to maintain an "Outperform" rating for the company, indicating a strong confidence in its potential for growth in the market.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.